Baolingbao Biology Co Ltd Market Cap ($419.24 Million)
Market Cap & Net Worth: Baolingbao Biology Co Ltd (002286)
Baolingbao Biology Co Ltd market cap. Baolingbao Biology Co Ltd (SHE:002286) has a market capitalization of $419.24 Million (CN¥2.87 Billion) as of November 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #12811 globally and #3689 in its home market, demonstrating a -8.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Baolingbao Biology Co Ltd's stock price CN¥7.54 by its total outstanding shares 379977380 (379.98 Million). Also see Baolingbao Biology Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Baolingbao Biology Co Ltd Market Cap History (2015–2026)
Baolingbao Biology Co Ltd market cap history from 2015 to 2026. Data shows change from $756.41 Million to $419.24 Million (-5.21% CAGR). Check Baolingbao Biology Co Ltd (002286) share price today for real-time trading data and today's change.
Baolingbao Biology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Baolingbao Biology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Baolingbao Biology Co Ltd equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.18x
Baolingbao Biology Co Ltd's market cap is 0.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.30x
Baolingbao Biology Co Ltd's market cap is 3.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $879.04 Million | $1.38 Billion | $49.34 Million | 0.64x | 17.82x |
| 2017 | $513.33 Million | $1.59 Billion | $49.62 Million | 0.32x | 10.34x |
| 2018 | $290.71 Million | $1.73 Billion | $42.95 Million | 0.17x | 6.77x |
| 2019 | $322.21 Million | $1.81 Billion | $35.23 Million | 0.18x | 9.14x |
| 2020 | $612.39 Million | $2.05 Billion | $49.86 Million | 0.30x | 12.28x |
| 2021 | $730.14 Million | $2.76 Billion | $201.58 Million | 0.26x | 3.62x |
| 2022 | $493.65 Million | $2.71 Billion | $133.17 Million | 0.18x | 3.71x |
| 2023 | $445.29 Million | $2.52 Billion | $53.97 Million | 0.18x | 8.25x |
| 2024 | $410.35 Million | $2.40 Billion | $111.16 Million | 0.17x | 3.69x |
| 2025 | $497.09 Million | $2.75 Billion | $150.63 Million | 0.18x | 3.30x |
Competitor Companies of 002286 by Market Capitalization
Companies near Baolingbao Biology Co Ltd in the global market cap rankings as of November 1, 2026. Also see 002286 total assets for a full breakdown of the balance sheet.
Key companies related to Baolingbao Biology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Baolingbao Biology Co Ltd (2015–2026)
Market capitalization of Baolingbao Biology Co Ltd from 2015 to today. Between 2015 and today, Baolingbao Biology Co Ltd's market cap moved from $756.41 Million to $ 419.24 Million, with a yearly change of -5.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥419.24 Million | -15.66% |
| 2025 | CN¥497.09 Million | +21.14% |
| 2024 | CN¥410.35 Million | -7.85% |
| 2023 | CN¥445.29 Million | -9.80% |
| 2022 | CN¥493.65 Million | -32.39% |
| 2021 | CN¥730.14 Million | +19.23% |
| 2020 | CN¥612.39 Million | +90.06% |
| 2019 | CN¥322.21 Million | +10.83% |
| 2018 | CN¥290.71 Million | -43.37% |
| 2017 | CN¥513.33 Million | -41.60% |
| 2016 | CN¥879.04 Million | +16.21% |
| 2015 | CN¥756.41 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Baolingbao Biology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $419.24 Million USD |
| MoneyControl | $419.24 Million USD |
| MarketWatch | $419.24 Million USD |
| marketcap.company | $419.24 Million USD |
| Reuters | $419.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, a… Read more